Single-use ADC Reactor
The Mobius ADC Reactor is the first single-use reactor designed specifically for the manufacture of antibody drug conjugates.
MilliporeSigma Mobius ADC Reactor| © MilliporeSigma
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, introduced the Mobius ADC Reactor, a single-use reactor designed specifically for the manufacture of antibody drug conjugates (ADCs). The reactor is the first of its kind for ADC production, according to the company. The Mobius ADC Reactor is designed to meet the unique requirements for linking the necessary components for ADCs and aims to enable these critical therapies to be produced faster and more safely with faster turnaround times and fewer cross-contamination risks. Performance improvements using the single-use reactor include elimination of potent liquid waste and a 70% increase in efficiency. The reactor’s single-use assemblies are made of Ultimus Film technology, which provides enhanced bag strength, improved durability, and leak resistance.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
